HUP0500070A3 - Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder - Google Patents

Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder

Info

Publication number
HUP0500070A3
HUP0500070A3 HU0500070A HUP0500070A HUP0500070A3 HU P0500070 A3 HUP0500070 A3 HU P0500070A3 HU 0500070 A HU0500070 A HU 0500070A HU P0500070 A HUP0500070 A HU P0500070A HU P0500070 A3 HUP0500070 A3 HU P0500070A3
Authority
HU
Hungary
Prior art keywords
17betha
11betha
estra
benzodioxol
dien
Prior art date
Application number
HU0500070A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pop Test Cortisol Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pop Test Cortisol Llc filed Critical Pop Test Cortisol Llc
Publication of HUP0500070A2 publication Critical patent/HUP0500070A2/hu
Publication of HUP0500070A3 publication Critical patent/HUP0500070A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0500070A 2001-10-26 2002-10-21 Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder HUP0500070A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26
PCT/EP2002/011732 WO2003037354A1 (en) 2001-10-26 2002-10-21 USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Publications (2)

Publication Number Publication Date
HUP0500070A2 HUP0500070A2 (hu) 2005-04-28
HUP0500070A3 true HUP0500070A3 (en) 2012-09-28

Family

ID=8181136

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500070A HUP0500070A3 (en) 2001-10-26 2002-10-21 Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder

Country Status (26)

Country Link
US (1) US20040266863A1 (https=)
EP (2) EP1652526B1 (https=)
JP (1) JP4647909B2 (https=)
KR (1) KR20050038580A (https=)
CN (1) CN100531738C (https=)
AT (2) ATE317700T1 (https=)
AU (1) AU2002348996B2 (https=)
BR (1) BR0213466A (https=)
CA (1) CA2463446C (https=)
CY (1) CY1110173T1 (https=)
DE (2) DE60230936D1 (https=)
DK (1) DK1652526T3 (https=)
EC (1) ECSP045080A (https=)
ES (1) ES2319563T3 (https=)
HR (1) HRP20040370B1 (https=)
HU (1) HUP0500070A3 (https=)
IL (2) IL161248A0 (https=)
IS (1) IS2702B (https=)
MX (1) MXPA04003781A (https=)
NO (1) NO332978B1 (https=)
NZ (1) NZ532429A (https=)
PL (1) PL206687B1 (https=)
PT (1) PT1652526E (https=)
RU (1) RU2302245C2 (https=)
WO (1) WO2003037354A1 (https=)
ZA (1) ZA200403088B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス, インコーポレイテッド Il−2を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターiiアンタゴニストの使用
EP2671086B1 (en) * 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
CN1820756A (zh) * 2001-03-23 2006-08-23 科塞普特治疗公司 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
IL160649A0 (en) * 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome

Also Published As

Publication number Publication date
CA2463446C (en) 2010-02-23
EP1441739B1 (en) 2006-02-15
IL161248A (en) 2010-12-30
NO332978B1 (no) 2013-02-11
EP1652526A2 (en) 2006-05-03
US20040266863A1 (en) 2004-12-30
WO2003037354A1 (en) 2003-05-08
EP1652526A3 (en) 2006-08-02
DE60230936D1 (de) 2009-03-05
HUP0500070A2 (hu) 2005-04-28
ECSP045080A (es) 2004-06-28
PT1652526E (pt) 2009-02-06
ZA200403088B (en) 2005-01-24
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
CN100531738C (zh) 2009-08-26
BR0213466A (pt) 2004-11-09
IS7204A (is) 2004-03-31
ATE420649T1 (de) 2009-01-15
CA2463446A1 (en) 2003-05-08
CY1110173T1 (el) 2015-01-14
JP2005521637A (ja) 2005-07-21
HRP20040370A2 (en) 2004-08-31
EP1652526B1 (en) 2009-01-14
KR20050038580A (ko) 2005-04-27
PL206687B1 (pl) 2010-09-30
HRP20040370B1 (hr) 2012-09-30
CN1582153A (zh) 2005-02-16
JP4647909B2 (ja) 2011-03-09
NZ532429A (en) 2004-10-29
ATE317700T1 (de) 2006-03-15
IS2702B (is) 2010-11-15
DK1652526T3 (da) 2009-05-18
ES2319563T3 (es) 2009-05-08
IL161248A0 (en) 2004-09-27
HK1087357A1 (en) 2006-10-13
EP1441739A1 (en) 2004-08-04
PL369261A1 (en) 2005-04-18
AU2002348996B2 (en) 2008-06-05
DE60209248D1 (de) 2006-04-20
RU2004116082A (ru) 2005-05-10
MXPA04003781A (es) 2004-07-30

Similar Documents

Publication Publication Date Title
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
HUP0402063A3 (en) Indole-2-carboxamides process for producing them, pharmaceutical compositions containing them and use thereof
IL161041A0 (en) Mch antagonists for the treatment of obesity
EP1407785A4 (en) MEDICAL COMPOSITIONS
HUP0102732A3 (en) Substituted amids, their use for producing pharmaceutical compositions and pharmaceutical compositions containing them
EP1398040A4 (en) MEDICAL COMPOSITION
GB0109754D0 (en) Floor treatment compositions
HUP0400609A3 (en) Wet-skin treatment compositions
GB0222388D0 (en) Bone filler material
HUP0500070A3 (en) Use of (11betha,17betha)-11-(1,3-benzodioxol-5-yl)-17-(1-propynyl)-estra-4,9-dien-3-one for producing pharmaceutical compositions for the treatment of major depressive disorder
HUP0401042A3 (en) Pharmaceutical compositions suitable for treating primary insomnia
AU2002365093A8 (en) Therapeutic compositions
GB2380651B (en) Removable electron multileaf collimator
IL160600A0 (en) Use of polysubstituted indan-1-ol systems for the preparation of medicaments for the prophylaxis or treatment of obesity
EP1357898A4 (en) ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
HK1068097A (en) Use of (11beta, 17beta)-11- (1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one in the treatment of major depressive disorder
IL156547A0 (en) Pharmaceutical composition containing citalopram
IL157272A0 (en) Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
GB0123063D0 (en) Compositions for therapy
PL113507U1 (en) Apparatus for mechanically anchoring gypsum plaster
ZA200102866B (en) Treatment of phospho gypsum.
GB0117325D0 (en) Therapeutic compositions
GB0114955D0 (en) Therapeutic compositions
GB0116847D0 (en) Therapeutic compositions

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: N.V. ORGANON, NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

GB9A Succession in title

Owner name: POP TEST CORTISOL LLC, US

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL; N.V. ORGANON, NL

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished